Overview

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

Status:
Active, not recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous NSCLC, RCC, OC, or melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

BeiGene

Treatments:

Antibodies